Prof. Dirk Jager

About Prof. Dirk Jager

Prof. Dr. med. Dirk Jäger is an internationally renowned Medical Oncologist and tumour immunology pioneer with 32+ years of experience. Since 2005, he has been Medical Director of the Department of Medical Oncology at Heidelberg University Hospital (UKHD) and Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg, where he leads translation of innovative immunotherapies — checkpoint inhibitors, cellular therapies and cancer vaccines — into early-phase clinical trials. He is widely regarded as one of the leading Medical Oncologist specialists in Heidelberg, Germany for international cancer patients seeking advanced immunotherapy.

32+ years of clinical and research experience in medical oncology and tumour immunology
Medical Director — Department of Medical Oncology, Heidelberg University Hospital (UKHD)
Managing Director — National Center for Tumor Diseases (NCT) Heidelberg (since 1 July 2005)
Head, Clinical Cooperation Unit “Applied Tumor Immunity” — German Cancer Research Center (DKFZ) (since 2013)
Board Member — NCT Heidelberg Comprehensive Cancer Center
Member, Clinical Leadership Committee — Cancer Research Institute (CRI), New York

Qualifications & Credentials

Medical Degrees

Medical Studies (Graduation) — Universities of Lübeck and Freiburg, Germany, 1985–1991
Practical Year — Karlsruhe Municipal Hospital, Germany
Doctorate (Dr. med. / MD) — Germany
Habilitation in Internal Medicine — Mainz University Clinic, 2003
Professor (Univ.-Prof.) of Medical Oncology — Medical Faculty, Heidelberg University

Fellowships & Special Training

Two-year Research Fellowship — Cancer Research Institute (CRI), New York City, USA
Specialist Examination for Internal Medicine, 1998
Recognition of Specialisation in Haematology and Internal Oncology, 2003

Certifications & Accreditations

Board Certification in Internal Medicine — Germany
Board Certification in Haematology and Oncology — Germany
Baden-Württemberg State Medical Council — Registered Specialist
Member, Cancer Vaccine Collaborative — CRI & Ludwig Institute for Cancer Research, New York

Areas of Expertise

Major Conditions Treated

Solid Tumours (Lung, Gastrointestinal, Hepatobiliary, Pancreatic, Breast, Genitourinary)
Melanoma & Skin Cancers
Hodgkin and Non-Hodgkin Lymphomas
Multiple Myeloma
Acute & Chronic Leukaemias
Sarcomas & Rare Tumours
Hereditary Cancer Syndromes
Treatment-Refractory and Late-Line Cancers
Patients Eligible for Early-Phase Immunotherapy Trials

Sub-specialties

Cancer Immunotherapy & Early-Phase Clinical Trials: Translation of checkpoint inhibitors, cellular therapy (CAR-T), bispecific antibodies and cancer vaccines into first-in-human and early-phase trials — making him a leading Medical Oncologist specialist Heidelberg, Germany for cutting-edge immunotherapy.
Tumour Immunology & Translational Research: Applied Tumor Immunity (DKFZ Clinical Cooperation Unit) — supporting demand for the best Medical Oncologist doctor in Germany for translational immuno-oncology.
Comprehensive Cancer Care & Multidisciplinary Tumour Boards: Personalised, biomarker-guided systemic therapy for solid tumours and haematological malignancies at NCT Heidelberg.

Advanced Procedures & Treatments

Immunotherapy / Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)
CAR-T Cell Therapy (Adoptive Cellular Therapy)
Bispecific Antibody Therapy
Cancer Vaccines & Personalised Neoantigen Therapies
Targeted Therapy (Biomarker-Guided)
Standard & Investigational Chemotherapy Regimens
Hormonal Therapy (Breast, Prostate)
Multidisciplinary Tumour Board Assessments
Genetic / Molecular Tumour Profiling
Coordination of Bone Marrow / Stem Cell Transplantation
Early-Phase Clinical Trial Enrolment

List of Disease and Treatment for which Prof. Dirk Jager can be consulted

Professional Experience

Current Affiliation

Medical Director — Department of Medical Oncology (Medical Clinic VI), Heidelberg University Hospital (UKHD) (Present)
Managing Director — National Center for Tumor Diseases (NCT) Heidelberg (since 1 July 2005 – Present)
Head, Clinical Cooperation Unit “Applied Tumor Immunity” — German Cancer Research Center (DKFZ), Heidelberg (since 2013 – Present)
Head, NCT Program “Immunotherapy” — NCT Heidelberg (Present)
Board Member — NCT Heidelberg Comprehensive Cancer Center (Present)
Univ.-Prof. of Medical Oncology — Medical Faculty Heidelberg, Heidelberg University (Present)

Past Affiliations

Mainz University Clinic — Habilitation in Internal Medicine, 2003
Cancer Research Institute (CRI), New York City, USA — Research Fellow, 2-year fellowship
Karlsruhe Municipal Hospital, Germany — Practical Year
Universities of Lübeck and Freiburg, Germany — Medical Studies, 1985–1991

Academic & Research Roles

Univ.-Prof. of Medical Oncology — Medical Faculty Heidelberg
Member, Clinical Leadership Committee — Cancer Research Institute (CRI), New York
Affiliate / Partner — Cancer Vaccine Collaborative and Ludwig Institute for Cancer Research, New York
Author of multiple high-impact peer-reviewed publications in cancer immunotherapy and translational oncology
Active mentor for clinician-scientists and PhD candidates at NCT Heidelberg / DKFZ

Key Achievements

Founding Managing Director of NCT Heidelberg — one of Europe’s leading comprehensive cancer centres
Pioneered translation of immunotherapies into early-phase clinical trials in Germany
Built the Clinical Cooperation Unit “Applied Tumor Immunity” at DKFZ
Affiliate of the Ludwig Institute for Cancer Research and Cancer Vaccine Collaborative, New York

Awards & Recognitions

National & International Awards

Member, Clinical Leadership Committee — Cancer Research Institute (CRI), New York
Affiliate, Ludwig Institute for Cancer Research, New York

Professional Memberships

German Society for Hematology and Medical Oncology (DGHO)
German Cancer Society (DKG)
European Society for Medical Oncology (ESMO)
American Society of Clinical Oncology (ASCO)
Cancer Research Institute (CRI), New York — Clinical Leadership Committee
Cancer Vaccine Collaborative

Research & Publications

Published Papers (Selected)

Hannani D, Vétizou M, Enot D, et al. (incl. Jaeger D). Anticancer Immunotherapy by CTLA-4 Blockade: Obligatory Contribution of IL-2 Receptors and Negative Prognostic Impact of Soluble CD25. Cell Research. 2015;25(2):208–224.
Krawczyk A, Arndt MA, Grosse-Hovest L, et al. (incl. Jäger D). Overcoming Drug-Resistant Herpes Simplex Virus (HSV) Infection by a Humanised Antibody.
Jäger D, et al. Translational Programmes for Cancer Immunotherapy at NCT Heidelberg.
Jäger D, et al. Adoptive T-cell Therapy with Genetically Engineered CAR-T Cells in Leukaemia and Lymphoma — NCT / DKFZ Programme Overview.
Jäger D, et al. Cancer-Testis Antigens (CTA) and Their Use in Tumour Vaccination.
Multiple high-impact publications in cancer immunotherapy, tumour antigens and clinical trial outcomes.

Ongoing Research & Clinical Interests

Cancer immunotherapy and translation into early clinical trials
Adoptive cellular therapy with CAR-T cells
Antibody-based and bispecific immunotherapy
Cancer vaccines and personalised neoantigen therapies
Tumour immunology and applied tumor immunity (DKFZ CCU)
Biomarker discovery for immunotherapy response

Estimated Treatment Costs

Procedure / Consultation	Estimated Cost (EUR)	Estimated Cost (USD)
Medical Oncology Consultation	€350 – €700	$380 – $760
Multidisciplinary Tumour Board Review	€600 – €1,500	$650 – $1,630
Comprehensive Molecular Tumour Profiling	€2,500 – €6,000	$2,700 – $6,500
Standard Chemotherapy (per cycle)	€2,500 – €8,000	$2,700 – $8,700
Targeted Therapy (per month, drug-dependent)	€5,000 – €15,000	$5,400 – $16,300
Immunotherapy / Checkpoint Inhibitor (per cycle)	€6,000 – €18,000	$6,500 – $19,500
CAR-T Cell Therapy (per course, indicative)	€280,000 – €350,000	$304,000 – $380,000
Early-Phase Clinical Trial (Investigational Drug)	Often Trial-Funded	Often Trial-Funded
Inpatient Oncology Stay (per day)	€800 – €1,800	$870 – $1,960

*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.

Frequently Asked Questions

1. What advanced technologies does Prof. Dr. med. Dirk Jäger use in Medical Oncologist treatment?

Prof. Dr. med. Dirk Jäger employs the latest evidence-based tools and minimally invasive techniques relevant to Medical Oncologist. Virtual consultations and remote second opinions are also available to international patients. Contact Cancer Rounds for a detailed technology overview specific to your case.

2. What conditions does Prof. Dr. med. Dirk Jäger specialize in treating?

Prof. Dr. med. Dirk Jäger is a specialist in Medical Oncologist, treating a broad spectrum of conditions in this field — including both common presentations and complex, rare cases. International patients seek treatment for conditions requiring expert Medical Oncologist care in Heidelberg, Germany.

3. How do I book an appointment with Prof. Dr. med. Dirk Jäger?

Appointments with Prof. Dr. med. Dirk Jäger can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.

4. Can international patients receive treatment from Prof. Dr. med. Dirk Jäger?

Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. med. Dirk Jäger, including medical visa invitation letters, airport transfers, and local accommodation coordination.

5. What support is available for international patients?

International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.

6. Does Prof. Dr. med. Dirk Jäger offer second opinions for Medical Oncologist cases?

Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert Medical Oncologist specialist in Heidelberg, Germany.

About Prof. Dirk Jager